GeneDx Holdings stock
WGSNASDAQGeneDx Holdings Corp., HealthcareISIN US81663L2007
37Score 37 out of 100, Weak
Price and trend
44 / 100
Price history
−62% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 26% below it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 69% below its 52-week high. Largest decline in 6 years: 100% (February 2021 to November 2023).
Chart figures for advanced users
- SMA 50$74.53
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$70.13
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$34.51
- The lowest closing price of the last twelve months.
- Resistance$167.52
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- GeneDx Holdings Corp. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $1.55B, is number 32 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $427.54M (up 40% year on year) and a loss of $21.02M.
- For fiscal 2026, analysts expect on average revenue of $482.26M (up 12.8%) and adjusted earnings per share of $0.10 (down 92.9%).
Show more
- MEQIRI Score 37 out of 100 (Weak): rank 606 of 714 in Healthcare, median 53.
- Our model puts fair value at $32.63, with the price 69% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 88.4% a year through 2028 (estimates from 4 analysts).Growth 67
- Growing faster than its industryRevenue up 19% a year since 2020, Medical (Diagnostics & Research) median 6.6%.Growth 67
- More cash than debtCash $170.12M, financial debt $150M.
Weaknesses
- DilutionShare count up 163% since 2022.Capital allocation 18
- Loss-makingLoss of $111.05M over the last 12 months.Fundamentals 17
- Share price fell sharplyDown 63% over the last 12 months.Momentum 41
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- weak fundamentals
- high price swings
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $21.75 and expensive above $65.25 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9.4%. At 10.4% the fair value would be $27.34, at 8.4% it would be $40.25.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 14.6% on the twelve months before. Revenue has grown strongly since 2019, at around 14% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 70%, operating −3%, net −5%. Last 12 months: net −24%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 22 Feb 2027in 102 days
- Last reported
- 9 Nov 2026EPS reported $0.28 (expected $0.07)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.100.0%
- Revenue
- $482.26M0.0%
- Earnings per share
- $1.200.0%
- Revenue
- $598.95M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +8.9%2026 revenue guidance of $475 million to $490 million reaffirmed.
“We're reaffirming our full year guidance range of $475 million to $490 million in revenues.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 3 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $46.33M in total. 2 insiders sold, $2.97M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Stueland KatherineSale
16 Sept 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 10,501
- Price
- $97.61
- Value
- $1.03M
- Feeley KevinSale
16 Sept 2026, CHIEF FINANCIAL OFFICER
- Shares
- 3,728
- Price
- $97.61
- Value
- $363,892
- Stueland KatherineSale
9 Sept 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 3,692
- Price
- $84.22
- Value
- $310,932
Show 14 more
- Feeley KevinSale
9 Sept 2026, CHIEF FINANCIAL OFFICER
- Shares
- 1,285
- Price
- $84.22
- Value
- $108,220
- Feeley KevinSale
1 Sept 2026, CHIEF FINANCIAL OFFICER
- Shares
- 372
- Price
- $83.84
- Value
- $31,188
- Feeley KevinSale
16 Jun 2026, CHIEF FINANCIAL OFFICER
- Shares
- 3,729
- Price
- $60.77
- Value
- $226,597
- Stueland KatherineSale
16 Jun 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 10,501
- Price
- $60.77
- Value
- $638,104
- Feeley KevinSale
9 Jun 2026, CHIEF FINANCIAL OFFICER
- Shares
- 1,266
- Price
- $53.77
- Value
- $68,073
- Stueland KatherineSale
9 Jun 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 3,639
- Price
- $53.77
- Value
- $195,669
- Casdin Capital, LLCPurchase
5 Jun 2026, Board
- Shares
- 50,000
- Price
- $52.86
- Value
- $2.64M
- Casdin Capital, LLCPurchase
4 Jun 2026, Board
- Shares
- 150,000
- Price
- $56.44
- Value
- $8.47M
- Casdin Capital, LLCPurchase
20 May 2026, Board
- Shares
- 140,000
- Price
- $43.81
- Value
- $6.13M
- Casdin Capital, LLCPurchase
19 May 2026, Board
- Shares
- 185,000
- Price
- $42.60
- Value
- $7.88M
- Casdin Capital, LLCPurchase
18 May 2026, Board
- Shares
- 175,000
- Price
- $42.55
- Value
- $7.45M
- Meister Keith A.Purchase
15 May 2026, Board
- Shares
- 46,273
- Price
- $38.91
- Value
- $1.8M
- Meister Keith A.Purchase
14 May 2026, Board
- Shares
- 140,000
- Price
- $39.39
- Value
- $5.51M
- Meister Keith A.Purchase
13 May 2026, Board
- Shares
- 165,000
- Price
- $39.09
- Value
- $6.45M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at GeneDx Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- Vimian GroupVIMIAN.ST $2.23B58
- NeoGenomicsNEO $2.19B40
- VeracyteVCYT $2.03B53
- PersonalisPSNL $1.73B41
- OPKO HealthOPK $1.27B37
- Castle BiosciencesCSTL $1.05B43
- Fulgent GeneticsFLGT $718.03M36
- Myriad GeneticsMYGN $548.67M40
ETFs that hold GeneDx Holdings
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 1.28% | 0.50% | €127.06M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.15% | 0.40% | €1.49B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.06% | 0.30% | €185.82M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2021)
- Valuation signal Fairly valued since 11 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.